Detalhe da pesquisa
1.
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
N Engl J Med
; 2024 Jun 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38924756
2.
Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.
N Engl J Med
; 387(2): 120-131, 2022 07 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35658005
3.
High-dose alectinib for RET fusion-positive non-small cell lung cancer in the Blood First Assay Screening Trial.
Contemp Oncol (Pozn)
; 27(4): 217-223, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38405208
4.
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Lancet Oncol
; 22(7): 959-969, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34118197
5.
Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
J Natl Compr Canc Netw
; 19(8): 915-921, 2021 04 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33878726
6.
COPD-dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk.
Int J Cancer
; 147(3): 747-756, 2020 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31709530
7.
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
Cancer
; 126(22): 4867-4877, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32914866
8.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol
; 19(12): 1654-1667, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30413378
9.
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Lancet
; 389(10066): 255-265, 2017 01 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-27979383
10.
Rociletinib in EGFR-mutated non-small-cell lung cancer.
N Engl J Med
; 372(18): 1700-9, 2015 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-25923550
11.
Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Curr Treat Options Oncol
; 19(11): 53, 2018 09 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30203184
12.
The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Future Oncol
; 14(18): 1875-1882, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29536761
13.
Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.
Curr Treat Options Oncol
; 18(6): 36, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28534251
14.
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Lancet Oncol
; 17(11): 1497-1508, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27745820
15.
Whole-exome sequencing reveals genetic variability among lung cancer cases subphenotyped for emphysema.
Carcinogenesis
; 37(2): 139-144, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26717996
16.
Risk of brain metastases in patients with nonmetastatic lung cancer: Analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data.
Cancer
; 122(12): 1921-7, 2016 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27062154
17.
Predictive and Prognostic Biomarkers in Non-Small Cell Lung Cancer.
Semin Respir Crit Care Med
; 37(5): 760-770, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27732997
18.
Personalized Therapy of Non-small Cell Lung Cancer (NSCLC).
Adv Exp Med Biol
; 890: 203-22, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26703806
19.
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Lancet Oncol
; 16(8): 897-907, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26156651
20.
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Lancet Oncol
; 15(10): 1119-28, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25153538